• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    1/27/22 4:56:18 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    SC 13G/A 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 37)*
     
    Eli Lilly and Company 

    (Name of Issuer)
     
    Common Stock, Without Par Value

    (Title of Class of Securities)
     
    532457-10-8

    (CUSIP Number)
     
    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         x  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  532457-10-8      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     LILLY ENDOWMENT INC
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   o
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Indiana
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     107,463,810
       
    6 SHARED VOTING POWER
      
     0
       
    7 SOLE DISPOSITIVE POWER
      
     107,463,810
       
    8 SHARED DISPOSITIVE POWER
      
     0
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     107,463,810
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     11.23%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     CO
     

    FOOTNOTES
      
     The percent of class represented is based on 956,592,393 shares of common stock outstanding as of October 22, 2021, as reported on the Issuer’s Form 10 Q for the period ended September 30, 2021.
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    Eli Lilly and Company

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    Lilly Corporate Center, Indianapolis, Indiana 46285.

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    This statement is filed by Lilly Endowment Inc., a not for profit corporation organized under the laws of the State of Indiana. Lilly Endowment Inc. is an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986 and is a private foundation under Section 509(a) of the Code.

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office of Lilly Endowment Inc. is 2801 North Meridian Street, Indianapolis, Indiana 46208.

     
    (c)
    Citizenship
     
     
    Indiana

     
    (d)
    Title of Class of Securities
     
     
    Common Stock, Without Par Value

     
    (e)
    CUSIP Number
     
     
    532457-10-8

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 107,463,810

     
    (b)
    Percent of class: 11.23%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 107,463,810

     
    (ii)
    Shared power to vote or to direct the vote: 0

     
    (iii)
    Sole power to dispose or to direct the disposition of: 107,463,810

     
    (iv)
    Shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
    Not applicable
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    Not applicable
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not applicable
     
     
     

     
     
     
    Item 10.
    Certification
      
    Not applicable.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     Lilly Endowment Inc.
     
        
    Date: January 14, 2022
    By:
    /s/  Diane M. Stenson 
       Name: Diane M. Stenson 
       Title:  Vice President & Treasurer 
        
     
    Footnotes:
    Item 4: This information is provided as of December 31, 2021.

    Item 4(a): None of such shares are deemed to be beneficially owned by reason of the possession of Lilly Endowment Inc. of a right to acquire such shares.

    Item 4(b): The percent of class represented is based on 956,592,393 shares of common stock outstanding as of October 22, 2021, as reported on the Issuer’s Form 10 Q for the period ended September 30, 2021.

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $LLY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    6/5/2025Buy → Hold
    Erste Group
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    9/13/2024$1060.00Buy
    Citigroup
    8/12/2024$1025.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Lilly declares third-quarter 2025 dividend

      INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

      6/23/25 11:37:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

      Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily

      6/22/25 2:31:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    SEC Filings

    See more
    • SEC Form 11-K filed by Eli Lilly and Company

      11-K - ELI LILLY & Co (0000059478) (Filer)

      6/20/25 4:23:15 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Eli Lilly and Company

      SD - ELI LILLY & Co (0000059478) (Filer)

      5/9/25 4:12:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ELI LILLY & Co (0000059478) (Filer)

      5/8/25 4:34:55 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eli Lilly downgraded by Erste Group

      Erste Group downgraded Eli Lilly from Buy to Hold

      6/5/25 7:52:21 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eli Lilly downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Eli Lilly from Buy to Reduce and set a new price target of $700.00 from $1,150.00 previously

      4/28/25 8:33:23 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Eli Lilly with a new price target

      Cantor Fitzgerald initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $975.00

      4/22/25 7:32:42 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sulzberger Gabrielle was granted 6 shares, increasing direct ownership by 0.24% to 2,580 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:28:26 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Luciano Juan R was granted 18 shares, increasing direct ownership by 0.11% to 16,362 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:26:05 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hedley Mary Lynne was granted 12 shares, increasing direct ownership by 0.63% to 1,960 units (SEC Form 4)

      4 - ELI LILLY & Co (0000059478) (Issuer)

      6/17/25 6:23:14 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 31, 2024 - FDA Roundup: May 31, 2024

      For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

      5/31/24 3:22:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 7, 2024 - FDA Roundup: May 7, 2024

      For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

      5/7/24 4:10:24 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 5, 2023 - FDA Roundup: December 5, 2023

      For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

      12/5/23 5:00:21 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

      Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu

      11/13/24 9:30:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly appoints Lucas Montarce as executive vice president and chief financial officer

      INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage

      9/9/24 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Financials

    Live finance-specific insights

    See more
    • Lilly declares third-quarter 2025 dividend

      INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

      6/23/25 11:37:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly declares second-quarter 2025 dividend

      INDIANAPOLIS, May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries

      5/5/25 12:47:00 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly reports first-quarter 2025 financial results and highlights pipeline momentum

      Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges.Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion. INDIANAPOLIS, May 1, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. "Lilly had a solid start to the year

      5/1/25 6:45:00 AM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      10/23/24 5:17:34 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      2/13/24 5:04:42 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

      SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

      1/26/24 4:25:45 PM ET
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care